David A. Scheinberg, MD, PhD

Publications

306

Funding

5 View NIH portfolio on RePORTER ↗

Active

1 grant

PI
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
NCI · 2020–2027 · via NIH RePORTER
R35CA241894-07

Completed grants (4)

MPI
Project 2: Microbiota-based biomarkers and therapeutic strategies for intestinal graft vs host disease
NCI · 1997–2025 · via NIH RePORTER
P01CA023766-43
PI
Improving specificity of therapeutic antibodies for cancer.
NCI · 1991–2020 · via NIH RePORTER
R01CA055349-26
MPI
Targeted Alpha-particle Therapy
NCI · 1982–2011 · via NIH RePORTER
P01CA033049-26
PI
CLINICAL AND MOLECULAR CANCER RESEARCH TRAINING PROGRAM
NCI · 1992–2004 · via NIH RePORTER
K12CA001712-10S1

Mentoring

16 All publications with mentees →

1 MD student · 14 PhD students · 1 MD-PhD student

CB
Christopher Bourne
Immunology & Microbial Pathogenesis (PhD) · Class of 2023
- Host Interactions with Engineered T-cell Micropharmacies.
  Cancer immunology research · 2023
- Host-cell Interactions of Engineered T cell Micropharmacies.
  bioRxiv : the preprint server for biology · 2023
- Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.
  Blood · 2023
View all 11 →
AC
Aaron Chang
Biochemistry & Structural Biology (PhD) · Class of 2018
- Engineering CAR-T cells to activate small-molecule drugs in situ.
  Nature chemical biology · 2021
- Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.
  Cancer immunology research · 2020
- Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
  Cancer discovery · 2020
View all 11 →
ZA
Zita Aretz
Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
- CD8 co-receptor modulates the specificity profile of the 1G4 TCR against NY-ESO-1.
  Molecular therapy : the journal of the American Society of Gene Therapy · 2025
- Challenges and solutions for therapeutic TCR-based agents.
  Immunological reviews · 2023
- Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment.
  Blood advances · 2022
View all 7 →
CO
Claire Oh
Pharmacology (PhD) · Class of 2019
- Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.
  Cancer immunology research · 2020
- ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
  Cancer immunology research · 2019
- Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.
  Oncoimmunology · 2019
View all 7 →
KK
Keifer Kurtz
Pharmacology (PhD)
- Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.
  Theranostics · 2023
- Host Interactions with Engineered T-cell Micropharmacies.
  Cancer immunology research · 2023
- Host-cell Interactions of Engineered T cell Micropharmacies.
  bioRxiv : the preprint server for biology · 2023
View all 6 →
KV
Kristen Vogt
Tri-I Program in Chemical Biology (PhD) · Class of 2024
- Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.
  Science advances · 2025
- Host Interactions with Engineered T-cell Micropharmacies.
  Cancer immunology research · 2023
- Host-cell Interactions of Engineered T cell Micropharmacies.
  bioRxiv : the preprint server for biology · 2023
View all 5 →
HJ
Heather Jones
Pharmacology (PhD) · Class of 2022
- CD8 co-receptor modulates the specificity profile of the 1G4 TCR against NY-ESO-1.
  Molecular therapy : the journal of the American Society of Gene Therapy · 2025
- Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.
  Frontiers in immunology · 2021
- An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments.
  Journal of proteomics · 2020
View all 5 →
MD
Megan Dacek
Pharmacology (PhD) · Class of 2021
- Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.
  Molecular therapy : the journal of the American Society of Gene Therapy · 2021
- Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.
  Bioconjugate chemistry · 2021
- CAR Chase: Where Do Engineered Cells Go in Humans?
  Frontiers in oncology · 2020
View all 5 →
PW
Patrick Wallisch
Pharmacology (PhD)
- Metabolic engineering to facilitate anti-tumor immunity.
  Cancer cell · 2025
- Challenges and solutions for therapeutic TCR-based agents.
  Immunological reviews · 2023
- Host Interactions with Engineered T-cell Micropharmacies.
  Cancer immunology research · 2023
View all 5 →
SP
Stephanie Pierre
MD-PhD Program (MD-PhD)
- Challenges and solutions for therapeutic TCR-based agents.
  Immunological reviews · 2023
- Host Interactions with Engineered T-cell Micropharmacies.
  Cancer immunology research · 2023
- Host-cell Interactions of Engineered T cell Micropharmacies.
  bioRxiv : the preprint server for biology · 2023
View all 4 →
PS
Pedro Silberman
Pharmacology (PhD) · Class of 2023
- Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.
  Science advances · 2025
- Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
  Cancers · 2020
View all 2 →
WC
Winson Cai
Pharmacology (PhD) · Class of 2024
- Augmenting CAR T-cell Functions with LIGHT.
  Cancer immunology research · 2024
View all 1 →